Certain metal complexes have created their own benchmark in the category of cytotoxic drugs. Down the line, copper metal complexes are found among the most prominent biologically active agents of high reputation. Considering breast cancer as one of the epicenters in malignant tumors, a series of three new derivatives of copper(II) CuL1, CuL2 and CuL3 have been synthesized and characterized associated with newly developed ligands 2,2′-(((1E,1′E)-1,4-phenylene-bis(methanylylidene))bis(azanylylidene)) diphenol supported by 2,2-bipyridine. All the complexes appeared in tetracoordination with tetrahedral geometry. The complexes were made to bind with ct-DNA through groove binding as established by molecular docking and computational DFT studies carried out for the determination of the HOMO and LUMO interactions and ESP mapping. Further, confirmation of BSA binding with complexes was confirmed by UV and fluorescence spectral studies. All these copper complexes were subjected for DPPH assay to determine the antioxidant properties, cytotoxicity towards the breast adenocarcinoma was retrieved by MTT assay, dual staining and cell cycle analysis against MCF7 cell line. Eventually, new copper derivative CuL2 (IC50 = 30.20 μg/mL) was found to exhibit the highest anticancer activity as compared to CuL1 (IC50 = 41.07 μg/mL) and CuL3 (IC50 = 42.01 μg/mL).
Read full abstract